Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00483119 · ClinicalTrials.gov registry record · Phase 2
Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus
A Phase 2 study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00483119 is a Phase 2 study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 9 participants.
The verdict
NCT00483119, a Phase 2 study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to compare two standard treatments for pemphigus to determine which more effectively improves the clinical manifestations of the disease and decreases serum level of the autoantibodies which cause the disease.
Interventions
- DRUG cyclophosphamide
- DRUG intravenous immunoglobulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2007-04 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00483119
The ClinicalTrials.gov registry entry for NCT00483119 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which cyclophosphamide is the first listed.
NCT00483119 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00483119 about?
NCT00483119 is a clinical study titled "Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus". The purpose of this study is to compare two standard treatments for pemphigus to determine which more effectively improves the clinical manifestations of the disease and decreases serum level of the autoantibodies which cause the disease.
What is the current status of trial NCT00483119?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2007-04. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00483119?
The interventions under investigation include: cyclophosphamide (DRUG), intravenous immunoglobulin (DRUG).
Who is sponsoring clinical trial NCT00483119?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.